First Catalog Cancer Biochip for Sequence Capture Now Available from febit
febit holding gmbh announced today the launch of the first human cancer biochip for HybSelectâ, febit's highly automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute.
"Molecular signatures defined by large-scale gene expression profiling are at the forefront in developing new biomarkers and identifying new therapeutic targets," said Professor Eckart Meese, director of the Department of Human Molecular Genetics at Saarland University. "It is of utmost importance for our research on malignant brain cancer to obtain deep sequencing results of the 100 most relevant genes with high sequence coverage using the HybSelect technique. It is equally important to obtain these results within a short period of time and at low costs."
The availability of the automated HybSelect technology supports large-cohort NGS studies that aim to elucidate complex diseases such as cancer, drive forward personalized medicine and investigate new therapeutic delivery models. febit will stay at the forefront of cancer research and include key research study results in the next generation of febit's cancer biochips. A 2Mb exon cancer biochip will be available this summer and a 30Mb biochip is planned already for release in 2010.
Multiplex NGS studies based on sequence capture can be supplemented by other molecular fingerprinting methods, including mRNA and miRNA expression profiling. Both of these high-throughput methods can be performed using the same febit technology as HybSelect, thereby reducing capital expenditures and minimizing experimental variation. HybSelect and expression profiling can easily be performed in the researcher's lab operating a Geniom RT Analyzerâ from febit or by using febit's convenient Analytical Services.
Hummingbird Diagnostics GmbH
febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.
For its main applications - HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing and protein-coding or non-coding transcriptome profiling - the highly advanced microfluidics of the patented Geniom Biochip offers the highest degree of automation, flexibility and efficiency available.
For more information, please visit www.febit.com.
Diese Pressemitteilungen könnten Sie auch interessieren
Weitere Informationen zum Thema "Biotechnik":
KI im Unternehmen: das Für und Wider
Auf der einen Seite erleichtert der Einsatz von Künstlicher Intelligenz (KI) den Arbeitsalltag, steigert die Effizienz und führt zu einer besseren Kundenbindung. Für Unternehmen ergeben sich jedoch auch neue Schaden- und Haftungsszenarien.Weiterlesen